Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Each year, 10 million episodes are treated with antibiotics, but half of the time subsequent urine testing fails to confirm ...

EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.

Staphylococcus aureus infections remain a formidable health threat, responsible for the most infection-related deaths ...